Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results
Ogdie, Alexis Liu, Mei Glynn, Meghan Emeanuru, Kelechi Harrold, Leslie R Richter, Sven Guerette, Benoit Mease, Philip J.
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
OBJECTIVE: Therapeutic response was evaluated among new apremilast, methotrexate, or biologic disease-modifying anti-rheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).
METHODS: Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, methotrexate, or bDMARD and completing 6-month follow-up were included.
RESULTS: In total, 150 patients initiated monotherapy (apremilast: n=34; methotrexate: n=15; bDMARD: n=101). Apremilast initiators had higher baseline disease activity than methotrexate initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than methotrexate initiators and similar improvements to bDMARD initiators.
CONCLUSION: Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA.
Source
Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold L, Richter S, Guerette B, Mease PJ. Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. J Rheumatol. 2020 Nov 15:jrheum.191209. doi: 10.3899/jrheum.191209. Epub ahead of print. PMID: 33191289. Link to article on publisher's site